Laura Schakel
Bonn, NW 53121, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of Cancer.
Journal: Journal of medicinal chemistry
Published: May 01, 2026
Synthesis, Characterization, Interactions, and Immunomodulatory Function of Ectonucleotidase CD39/CD73 Inhibitor 8-Butylthioadenosine 5'-Monophosphate.
Journal: ACS pharmacology & translational science
Published: February 14, 2025
Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity.
Journal: Journal of medicinal chemistry
Published: August 15, 2024
Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity".
Journal: ACS pharmacology & translational science
Published: February 27, 2024
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.
Journal: ACS pharmacology & translational science
Published: November 10, 2023
Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results.
Journal: Journal of psychiatric research
Published: August 07, 2023
Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phospho-diesterase-1 (NPP1) - a promising target for the immunotherapy of cancer.
Journal: Frontiers in immunology
Published: February 24, 2023
Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39.
Journal: Bioorganic chemistry
Published: January 13, 2023
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Journal: Journal of medicinal chemistry
Published: December 08, 2022
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
Journal: Journal of medicinal chemistry
Published: September 15, 2022
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
Journal: Journal of medicinal chemistry
Published: June 16, 2022
Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: May 24, 2022
Last Updated: 09/26/2026